You are here

  • Home
  • Archive
  • Volume 23, Issue 6
  • Deprescribing cardiovascular drugs in low-risk patients increases the risk of uncontrolled blood pressure and LDL-cholesterol

Article Text

Article menu
Download PDFPDF
Commentary
Primary care
Deprescribing cardiovascular drugs in low-risk patients increases the risk of uncontrolled blood pressure and LDL-cholesterol
  1. Daniel Caldeira1,2,3
  1. 1 Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
  2. 2 Centro Cardiovascular daUniversidade de Lisboa - CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
  3. 3 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
  1. Correspondence to Professor Daniel Caldeira, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisboa, 1649-028, Portugal; dgcaldeira{at}hotmail.com

https://doi.org/10.1136/bmjebm-2018-110976

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Luymes CH, Poortvliet RKE, van Geloven N, et al. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med. 2018;16(1):5.

    Context

    The prescription of cardiovascular drugs in primary prevention may be challenging due to the risk of adverse drug reactions overcoming the benefits in a population with low cardiovascular risk.1 The impact of drug deprescription in this context is still unknown.

    Methods

    This was a multicentric, open-label, cluster randomised controlled trial comparing the effect of the deprescription of cardiovascular drugs versus usual care.2 The trial included patients aged between 40 and 70 years with a low risk of cardiovascular events treated with antihypertensive drugs or lipid-lowering drugs for more than 1 year. The primary outcome was the difference in …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.